Angiotensin I converting enzyme gene polymorphism and insulin resistance in patients with angina pectoris
Citation
T. Takezako et al., Angiotensin I converting enzyme gene polymorphism and insulin resistance in patients with angina pectoris, AM J HYPERT, 12(3), 1999, pp. 291-297
Categorie Soggetti
Cardiovascular & Respiratory Systems
Journal title
AMERICAN JOURNAL OF HYPERTENSION
SICI code
0895-7061(199903)12:3<291:AICEGP>2.0.ZU;2-R
Abstract
The association between insertion/deletion polymorphism of the angiotensin
I converting enzyme (ACE) gene and insulin resistance (IR) was investigated
in 64 consecutive patients (F/M: 11/53) with angina pectoris without clini
cally manifest diabetes mellitus who underwent diagnostic coronary angiogra
phy. The observed frequency distribution of ACE-ID genotypes did not deviat
e from that predicted from the Hardy-Weinberg equilibrium in this group. Pa
tients with the ACEID genotype had significantly lower IR, as assessed by a
n oral glucose tolerance test (OGTT) and by homeostatic model assessment (H
OMA), compared to those with the ACE-II genotype, as assessed by a multiple
comparison analysis. Patients were divided into two groups with low and hi
gh HOMA-IR, and the I allele was seen more frequently in the high HOMA-IR g
roup than in the low HOMA-IR group (0.62 v 0.47, respectively, by chi(2) te
st, P < .05). Logistic regression analysis showed that the odds ratio for i
nsulin resistance in patients with the II genotype, compared to those with
the ID and DD genotypes (assuming that the I allele has a recessive effect)
, was 4.0 (95% confidence interval, 1.2 to 16.5; P = .037), after adjusting
for the presence of significant coronary atherosclerosis. In conclusion, t
he D allele was not associated with higher insulin resistance in patients w
ith angina pectoris; that is, patients with the ID and DD genotypes were as
sociated with a significantly lower risk of insulin resistance, compared to
those with the II genotype. Am J Hypertens 1999;12:291-297 (C) 1999 Americ
an Journal of Hypertension, Ltd.